NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Feltner C, Grodensky C, Ebel C, et al. Serological Screening for Genital Herpes: An Evidence Review for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Dec. (Evidence Syntheses, No. 149.)
Serological Screening for Genital Herpes: An Evidence Review for the U.S. Preventive Services Task Force [Internet].
Show detailsTable 4Characteristics of Included Studies Assessing Antiviral Medications in Nonpregnant Adults (Key Questions 4 and 5)
| Author, Year Study Design Quality | Group 1 (N) Group 2 (N) | Duration, weeks | Population | Recruitment Setting; Country | HSV-2 Test | Mean Age (SD) | % Female | % Nonwhite | % HSV-1 Positive |
|---|---|---|---|---|---|---|---|---|---|
| Sperling, 200881 RCT (crossover) Fair | Total (63) Valacyclovir 1g daily first (36) Placebo first (37) | 8 active; 8 placebo | Adults age ≥18 years who are seropositive for HSV-2 with no active lesions or symptoms consistent with genital herpes and no history of recurrent or undiagnosed symptoms consistent with genital herpes | 13 clinical settings* (STI clinics, primary care clinics, and gynecology practices) United States | HerpeSelect† | 37 (NR) | 75 | 35 | 56–57 |
| Leone, 200782 RCT (crossover) Fair | Total (66) Famciclovir 250 mg twice daily first (NR) Placebo first (NR) | 6 active; 6 placebo | Adults age ≥18 years who are seropositive for HSV-2 with no history of symptomatic genital herpes | 7 centers (not otherwise specified) United States | Western blot | Median (range): 38 (18–68) | 64 | 35 | 55 |
| Corey, 200476 Kim, 200883 RCT (parallel) Fair | Total (1484 couples) Valacyclovir 500 mg once daily (743 couples) Placebo (741 couples) | 32 | Adults age ≥18 years; HSV-2 serodiscordant heterosexual couples | 96 study sites (not otherwise specified) United States, Canada, Europe, Latin America, Australia | Western blot | Median (range): 34–34 (18–76) | 33 | 10–11 | 70 |
| Mujugira84 RCT (parallel) Fair | Total (937 couples) Acyclovir 400 mg twice daily (458 couples) Placebo (453 couples) | 96 | HSV-2 serodiscordant heterosexual couples enrolled into the Partners in Prevention HSV/HIV Transmission study38; couples were also serodiscordant for HIV (HSV-2 infected partners were also infected with HIV) | 14 study sites (not specified) Kenya, Rwanda, Tanzania, Uganda, Botswana, South Africa, Zambia | HerpeSelect‡ | Median: 31 (IQR, 27–38) | 12 | NR | ≥99 |
- *
Participants had either undergone specific HSV serologic testing as part of their clinical care or in response to local advertisements offering free HSV serologic testing.
- †
Samples with an index value of 1.1 to 3.5 were confirmed with HSV-2 IgG inhibition assay to eliminate false-positive test results.
- ‡
Samples with an index value of ≥3.5 were considered positive to improve test specificity, and confirmed by Western blot.
Abbreviations: HSV=herpes simplex virus; IQR=interquartile range; N=number; NR=not reported; RCT=randomized, controlled trial; SD=standard deviation.
- Table 4, Characteristics of Included Studies Assessing Antiviral Medications in ...Table 4, Characteristics of Included Studies Assessing Antiviral Medications in Nonpregnant Adults (Key Questions 4 and 5) - Serological Screening for Genital Herpes
Your browsing activity is empty.
Activity recording is turned off.
See more...